国药现代子公司获注射用尼可地尔药品注册证书

Core Viewpoint - The company has received approval for the injectable Nicorandil, which is primarily used for treating unstable angina, enhancing its product portfolio in the cardiovascular field [1] Group 1 - The company's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Nicorandil from the National Medical Products Administration [1] - The approval is considered equivalent to passing the consistency evaluation, which will enrich the company's cardiovascular product offerings [1] - This development is expected to strengthen the company's overall market competitiveness in related medication fields and bring positive impacts for future growth [1]